Treatment of 1st line NSCLC with a focus on ALK+ patients

In this e-learning, lung cancer experts from different countries in Europe are discussing the challenges and opportunities in treating patients with ALK positive non-small cell lung cancer.

There are multiple next-generation ALK inhibitors available with distinct tolerance profiles and different dosing schedules.

Selecting a frontline ALK inhibitor has to do with several parameters but testing for ALK rearrangements is core in these patients.

Do you wish to learn more regarding ALK+ NSCLC from national and international experts? Start the e-learning!

CME accreditation

  • Dutch Society of Pulmonology and Tuberculosis (NVALT) – 2 points awarded

Program e-learning

MODULE 1 (theory)

Immunotherapy in 1st line among ALK positive patients

Prof. Joachim Aerts

Treatment of 1st line ALK+ patients: testing and sequencing

Dr. Laura Mezquita

MODULE 2 (clinical cases)

Lung Adenocarcinoma ALK+ cT4NxM1c (8aUICC)

Dr. Luis Paz-Ares

Treatment without knowing the genetic profile

Prof. Joachim Aerts

Frontline treatment of ALK+ advanced NSCLC                     

Dr. Maurice Pérol

Scientific Expert Panel

Please enter your bignummer